CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.
View all episodes
By BiotechTV
4.3
66 ratings
CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.
3,368 Listeners
415 Listeners
1,644 Listeners
948 Listeners
123 Listeners
321 Listeners
211 Listeners
6,444 Listeners
62 Listeners
10,018 Listeners
86 Listeners
34 Listeners
20 Listeners
0 Listeners
4 Listeners
2 Listeners
5 Listeners
37 Listeners